- Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
- Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
- Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Key statistics
On Friday, Sonnet Biotherapeutics Holdings Inc (SONN:NAQ) closed at 0.91, 4.54% above its 52-week low of 0.8705, set on Jun 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.8857 |
---|---|
High | 0.9598 |
Low | 0.88 |
Bid | 0.89 |
Offer | 0.90 |
Previous close | 0.88 |
Average volume | 65.17k |
---|---|
Shares outstanding | 3.11m |
Free float | 2.83m |
P/E (TTM) | -- |
Market cap | 2.83m USD |
EPS (TTM) | -5.28 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:46 BST.
More ▼